Metabolic & Weight
Peptides that influence metabolism, fat burning, and body composition
16 peptide profiles in this category. Browse the full directory to explore all 167 research peptides.
Adipotide (FTPP)
A pro-apoptotic peptide that selectively destroys the vasculature supplying white adipose tissue, producing targeted fat loss without systemic metabolic effects.
AOD-9604
A modified fragment of growth hormone (hGH 177-191) that specifically activates fat metabolism without the growth-promoting or insulin-desensitising effects of hGH.
Peptide YY Analogue (Cagrilintide Component)
Native GLP-1 (7-37) is the endogenous 31-aa incretin secreted by intestinal L-cells. It potentiates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite. The structural template for semaglutide, liraglutide, and exenatide.
Semaglutide
A GLP-1 receptor agonist best known as Ozempic/Wegovy, used for weight management and diabetes.
Fragment 176-191
The isolated lipolytic fragment of human growth hormone - 16 amino acids that target fat burning without the growth-promoting or diabetogenic effects of full hGH.
Glucagon
Glucagon is the 29-aa counter-regulatory hormone from pancreatic alpha cells that stimulates hepatic glycogenolysis, gluconeogenesis, and lipolysis in response to hypoglycemia. Its receptor agonism is incorporated into retatrutide and other triple-agonist drug candidates.
AICAR
An AMPK activator and metabolic modulator that mimics the cellular effects of exercise - enhancing glucose uptake, mitochondrial biogenesis, and fat oxidation.
Retatrutide
A triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously - producing the highest weight loss of any peptide in clinical trials to date.
Pramlintide
Pramlintide (Symlin) is the synthetic non-aggregating amylin analogue with three proline substitutions. FDA-approved as adjunct to insulin. Reduces postprandial glucose ~30%, suppresses glucagon, and produces 1-2 kg weight loss.
Suprefort
Suprefort is a Khavinson short peptide bioregulator for the pancreas. Proposed to support pancreatic cell gene regulation and beta cell function in aging models. Used in anti-aging research involving metabolic aging and pancreatic reserve.
GIP (Glucose-dependent Insulinotropic Polypeptide)
GIP is a 42-aa incretin secreted by duodenal K-cells that potentiates insulin secretion in a glucose-dependent manner. Tirzepatide's superiority over semaglutide is attributed to its additional GIPR co-agonism.
Pancragen
A tetrapeptide pancreatic bioregulator (Lys-Glu-Asp-Trp) from the Khavinson series that supports beta cell differentiation, insulin regulation, and pancreatic tissue longevity.
Peptide YY (PYY 3-36)
PYY 3-36 is the biologically active form of the gut satiety peptide secreted post-meal by L-cells. It reduces appetite via Y2 receptor agonism in the hypothalamic arcuate nucleus. Human IV infusion studies demonstrate significantly reduced caloric intake.
Oxyntomodulin
Oxyntomodulin is a 37-aa gut peptide and dual GLP-1R/glucagon receptor agonist released post-meal. Its combined receptor activity suppresses appetite while simultaneously increasing energy expenditure — the mechanistic rationale for multi-receptor incretin drugs.
Tirzepatide
A dual GIP/GLP-1 receptor agonist (Mounjaro/Zepbound) producing the highest weight loss rates of any approved peptide therapy.
Amylin
Amylin (IAPP) is a 37-aa peptide co-secreted with insulin by beta cells that suppresses glucagon, slows gastric emptying, and reduces food intake. Deficient in T1D and late T2D. Pramlintide is its FDA-approved synthetic analogue.
Research Tools
Use these tools to plan and compare Metabolic & Weight protocols.